Clinical Trial Detail

NCT ID NCT01964924
Title Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

Therapies

Trametinib + GSK2141795

Age Groups: adult

Additional content available in CKB BOOST